BDX Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Loading...
Becton Dickinson and Co (BDX) is a good buy for a beginner investor with a long-term strategy and $50,000-$100,000 available for investment. The company's strong financial performance, positive analyst sentiment, and recent strategic moves such as the LifeSciences sale and bond buyback plan indicate a solid growth trajectory. Despite short-term technical weakness, the long-term fundamentals remain strong.
The stock's MACD is negatively expanding (-0.841), indicating bearish momentum. RSI is at 29.69, suggesting the stock is nearing oversold territory. The price is trading near the support level of 176.633, with resistance at 181.156. Moving averages are converging, showing no clear trend. Overall, technicals indicate short-term weakness but potential for a rebound.
Hedge funds are significantly increasing their positions in BDX, with a 956.90% increase in buying over the last quarter.
The company announced a $2 billion bond buyback plan to optimize its capital structure.
The sale of the LifeSciences Bioprocessing segment creates a more focused MedTech company, which analysts believe will drive faster and more consistent growth.
Strong financial performance in Q1 2026, with revenue, net income, EPS, and gross margin all showing YoY growth.
Short-term technical indicators suggest bearish momentum.
Analyst price targets are mixed, with some downgrades reflecting concerns about flat organic growth and top-line pressure in key areas.
In Q1 2026, BDX reported revenue growth of 1.63% YoY to $5.25 billion, net income growth of 26.07% YoY to $382 million, EPS growth of 28.85% YoY to $1.34, and gross margin improvement of 5.13% to 45.91%. These figures indicate strong financial health and operational efficiency.
Analyst sentiment is generally positive, with multiple Buy ratings and price targets ranging from $170 to $233. Recent upgrades reflect optimism about the company's strategic moves and financial performance, while some downgrades highlight concerns about growth recovery and 2026 being a transition year.
